IPO Year: 2023
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/28/2024 | $23.00 → $6.00 | Buy → Neutral | Goldman |
5/2/2024 | $32.00 | Buy | H.C. Wainwright |
3/25/2024 | $26.00 | Outperform | Leerink Partners |
8/8/2023 | Outperform | TD Cowen | |
8/8/2023 | $67.00 | Overweight | Piper Sandler |
8/8/2023 | $33.00 | Buy | Goldman |
8/8/2023 | $30.00 | Mkt Outperform | JMP Securities |
SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)
SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. "We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress Preparations are ongoing to initiate a Phase 3 clinical development program for denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, joined the Board of Directors effective August 1, 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $188.5 million as of June 30, 2024 SAN MATEO, Calif., Aug. 14, 202
SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that it will host a conference call and webcast on Thursday, June 13, 2024, at 9.30 AM PT / 12:30 PM ET. The event will feature Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, who was the Principal Investigator on the Phase 2b FASCINATE-2 clinical trial and serves as a scientific advi
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
3 - Sagimet Biosciences Inc. (0001400118) (Issuer)
3 - Sagimet Biosciences Inc. (0001400118) (Issuer)
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
Goldman Sachs analyst Andrea Tan maintains Sagimet Biosciences (NASDAQ:SGMT) with a Neutral and lowers the price target from $23 to $6.
HC Wainwright & Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $32 price target.
JMP Securities analyst Jonathan Wolleben reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and maintains $48 price target.
HC Wainwright & Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $32 price target.
Sagimet Biosciences Inc (NASDAQ:SGMT) presented data from its FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients at the European Association for the Study of the Liver (EASL) Congress. Related: What’s Going On With Fatty Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for MASH. Topline data was announced for the FASCINATE-2 Phase 2b study in January. In the EASL presentation, additional 52-week ITT and F3 subgroup efficacy data
Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for accelerated approval in MASH. Denifanstat showed a statistically significant improvement in liver fibrosis ≥1-stage without worsening of MASH in the ITT population, including in patients with baseline stage 3 fibrosis Statistical significance also shown in improvement of liver fibrosis ≥2-stage without worsening of MASH in the mITT population, including in patients with baseline stage 3 fibrosis Tripalmitin, a biomarker of denifanstat activity, showed an early and sustained reduction in
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower. At the EASL International Liver Congress 2024, Eli Lilly And Co (NYSE:LLY) shared an abstract highlighting fibrosis results from a Phase 2 trial of tirzepatide in patients with metabolic dysfunction-associated steatohepatitis (MASH). Tirzepatide is a key ingredient in popular Mounjaro for diabetes and Zepbound for weight loss. Other companies working on MASH candidates include 89bio Inc (NASDAQ:ETNB), Akero Therapeutics Inc (NASDAQ:AKRO), and Viking Therapeutics Inc (NASDAQ:VKTX). The Phase 2 SYNERGY-NASH trial studied three doses (5 mg, 10 mg or 15
JMP Securities analyst Jonathan Wolleben reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and maintains $48 price target.
HC Wainwright & Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $32 price target.
Goldman downgraded Sagimet Biosciences from Buy to Neutral and set a new price target of $6.00 from $23.00 previously
H.C. Wainwright initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $32.00
Leerink Partners initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $26.00
TD Cowen initiated coverage of Sagimet Biosciences with a rating of Outperform
Piper Sandler initiated coverage of Sagimet Biosciences with a rating of Overweight and set a new price target of $67.00
Goldman initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $33.00
JMP Securities initiated coverage of Sagimet Biosciences with a rating of Mkt Outperform and set a new price target of $30.00
EFFECT - Sagimet Biosciences Inc. (0001400118) (Filer)
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
S-3 - Sagimet Biosciences Inc. (0001400118) (Filer)
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
10-Q - Sagimet Biosciences Inc. (0001400118) (Filer)
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
8-K/A - Sagimet Biosciences Inc. (0001400118) (Filer)
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress Preparations are ongoing to initiate a Phase 3 clinical development program for denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, joined the Board of Directors effective August 1, 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $188.5 million as of June 30, 2024 SAN MATEO, Calif., Aug. 14, 202
SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024. "We are thrilled to welcome Anne and Jennifer to our board as we prepare to start our Phase 3 clinical development of denifanstat in MASH this year," said Dave Happel, CEO of Sagimet. "Their expertise will be critical as we advance denifanstat into late-
SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that it will host a conference call and webcast on Thursday, June 13, 2024, at 9.30 AM PT / 12:30 PM ET. The event will feature Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, who was the Principal Investigator on the Phase 2b FASCINATE-2 clinical trial and serves as a scientific advi
Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for accelerated approval in MASH Denifanstat showed a statistically significant improvement in liver fibrosis ≥1-stage without worsening of MASH in the ITT population, including in patients with baseline stage 3 fibrosis Statistical significance also shown in improvement of liver fibrosis ≥2-stage without worsening of MASH in the mITT population, including in patients with baseline stage 3 fibrosis Tripalmitin, a biomarker of denifanstat activity, showed an early and sustained reductio
SAN MATEO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual investor and analyst day on Thursday, May 23, 2024 at 1:00 PM ET. To register, click here. The event will feature Scott L. Friedman, MD (Icahn School of Medicine at Mount Sinai) who will discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH). It will also include a discussion on the Company's lead drug candidate, den
Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking place in Milan, Italy from June 5-8, 2024 End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) expected in the second quarter of 2024 Preparations are underway to start a pivotal Phase 3 trial evaluating denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $193.7 million as of March 31, 2024 SAN MATEO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet,
SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced a General Session oral presentation of denifanstat Phase 2b FASCINATE-2 study data in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the European Association for the Study of the Liver (EASL) International Liver Congress 2024 held in Milan, Italy from June 5-8, 2024. EASL Presentation Details: General Session Oral Presentation Title: Denifanstat, a fatty acid synthase (FASN) inhibitor
SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. "We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an
SAN MATEO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual investor and analyst day on Friday, May 3, 2024 at 12:30 PM ET. To register, click here. The event will feature Stephen Harrison, MD (Visiting Professor of Hepatology at Radcliffe Department of Medicine, University of Oxford) who will discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH). It will also include a di
SAN MATEO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the completion of a Phase 1 hepatic impairment study with denifanstat, a selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This study was designed to assess the safety and pharmacokinetics of denifanstat in subjects with hepatic impairment, a typical requirement of development programs in MASH. A total of 38 subjects were enrolled and complete
4 - Sagimet Biosciences Inc. (0001400118) (Issuer)